Ocunexus Therapeutics
San Diego
About Ocunexus Therapeutics
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $78.6M
- Last round: Series Unknown (Jan 2021)
- Website: inflammx.com
- Phone: (858) 677-0474
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/ocunexus-therapeutics-137785 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.